Cannabinoid | High Risk

Cannabis Flower THC 25% (Dried Herb) (Cannatrek T25 Ruby)

What to know about Cannabis Flower THC 25% (Dried Herb) — also sold as Cannatrek T25 Ruby, ANTG Solace: uses, side effects, interactions, and safety considerations for people taking it or caring for someone who is.

Cannabis Flower THC 25% (Dried Herb) (brand names: Cannatrek T25 Ruby, ANTG Solace) is classified as High risk (7 risk points) by AllMeds. It is a S8 medication under the TGA in Australia. High-potency flower, significant impairment

Key Takeaways

  • TGA Schedule: S8 in Australia
  • Risk level: High (7 points)

Scheduling and Classification

Jurisdiction Classification Status
Australia (TGA) S8 Not PBS listed

Risk Profile

Risk Level High
Risk Points 7
CNS Depressant No
Respiratory Risk No

High-potency flower, significant impairment

How Cannabis Flower THC 25% (Dried Herb) is regulated

Cannabis Flower THC 25% (Dried Herb) is overseen by medicines regulators in each country. The rules below explain how it's scheduled, what oversight applies, and what to discuss with your doctor or pharmacist before starting, changing, or stopping this medication.

Australia TGA / PBS / State Schemes

Classified as S8 under the Therapeutic Goods Administration (TGA).

Clinical Evidence

  • Medicinal cannabis prescriptions surge in Australia - ABC News (2024)

    Reporting on the rapid growth of medicinal cannabis prescriptions in Australia via SAS pathway. Notes concerns about evidence base.

    National broadcaster

  • TGA: Medicinal Cannabis Access — THC Products (S8) - TGA (2024)

    THC products are Schedule 8. Require SAS-B or Authorised Prescriber pathway. Strict prescribing and monitoring requirements.

    TGA regulatory framework

  • SIRA: Medicinal Cannabis — S8 Requirements and Driving Impairment - SIRA NSW (2023)

    SIRA notes THC products carry driving impairment risk. NSW drug-driving laws apply regardless of medical authorisation. Insurer approval required.

    NSW workers comp regulator

  • Cannabis-based medicines for chronic neuropathic pain — Cochrane Review - Mücke M, et al. (Cochrane) (2018)

    Cochrane review finding low-quality evidence that cannabis-based medicines may provide some relief for chronic neuropathic pain. Significant adverse effects noted.

    Cochrane systematic review — gold standard for evidence synthesis

Check this medication against your full medication list

Run a full risk assessment including Cannabis Flower THC 25% (Dried Herb) interactions and compliance checks.

Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.

Try it free → Talk to Sales →

Important: This page is general health information, not personal medical advice. If you have questions about your medication — including starting it, stopping it, changing the dose, or combining it with something else — speak with your doctor or pharmacist. For an emergency or suspected overdose, call your local emergency number or poison information service immediately. Information is drawn from regulator and clinical guideline sources (TGA, FDA, MHRA, NICE, PBS, CDC); see our methodology for details.